NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidates
read at Endpoints ↗DealPositive
NeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million.
The capital will be used to move three clinical-stage drugs focused on brain health into later stages of development.
The company is led by CEO Joan Shen, formerly of I-Mab, and the funding underscores investor confidence in its trans-Pacific development strategy.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “US-China biotech NeuShen gets $80M to develop brain-health drugs”
read at Endpoints ↗87 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that